萬國法律事務所

The first approval of preference under Development Act for Bio-Tech Medicine Industry, which was published and put into effect 29 February, 2008, has been issued on 1 May, 2008.  After an investigation conducted by a cross-department board, Microbio Biotechnology Co. Ltd. (“Microbio”) has been approved as the first, and the only as of now, to be entitled to the preference measure under the Act.  By virtue of the approval, shareholders of Microbio, who participated in the capital increase for case, will enjoy 20 % tax exemption.

Two corporations applied for the preference measures, but only Microbio acquire the approval in consideration of Microbio’s active efforts on developing and its progress in new biotechnology medicine, including its DCB-WH1 diabetes medicine, which is likely to be the Taiwan’s first medicine patent issued by FDA of United States.